The market was valued at approximately USD 112.87 million in 2026 and is projected to reach around USD 225.87 million by 2033, growing at a CAGR of about 10.2% during the forecast period, 2026-2033.
Growth is primarily fuelled by the rising incidence of monkeypox cases across regions, prompting governments and health organizations to expand vaccination programs and stockpiling strategies. Increased awareness, emergency use authorizations, and global initiatives led by organizations such as the World Health Organization are further accelerating vaccine demand. Additionally, advancements in smallpox-based vaccines, such as next-generation non-replicating vaccines, are enhancing safety and efficacy.
North America currently dominates the market due to strong healthcare infrastructure and high vaccine procurement, while Europe and Asia-Pacific are emerging as high-growth regions. However, limited number of approved vaccines and supply constraints remain key challenges. Overall, the market is expected to grow steadily, supported by ongoing R&D investments, strategic collaborations, and increasing focus on infectious disease preparedness worldwide.
The global monkeypox vaccine market is witnessing rapid evolution driven by rising outbreak preparedness and technological innovation. A key trend is the expansion of vaccine manufacturing capacity and global stockpiling, with companies increasing production to meet emergency demand and strengthen public health readiness. Additionally, governments and regional bodies are entering long-term procurement agreements to secure vaccine supply, reflecting a shift toward proactive pandemic preparedness.
Another major trend is the development of next-generation vaccines, including non-replicating and safer smallpox-based vaccines with improved efficacy and reduced side effects. Growing research activity following recent outbreaks has significantly accelerated innovation in this field. Furthermore, increasing collaboration between pharmaceutical companies, governments, and research institutions is driving faster development and distribution of vaccines globally. Rising awareness and sustained R&D investments continue to shape a dynamic and expanding market landscape.
Segmentation: The Global Monkeypox Vaccine Market is segmented By Vaccine Type (Live Attenuated Vaccines, Non-Replicating Vaccines, and Replicating Vaccines), Product Type (Smallpox-based Vaccines, and Next-Generation Monkeypox Vaccines), Route of Administration (Subcutaneous, and Intradermal), Indication (Pre-Exposure Prophylaxis, and Post-Exposure Prophylaxis), End User (Hospitals, Public Health Agencies, and Vaccination Centers), and Geography (North America, Europe, Asia-Pacific, Middle East and Africa, and South America). The report provides the value (in USD million) for the above segments.
Market Drivers:
The primary drivers of the global monkeypox vaccine market is the increasing incidence of monkeypox outbreaks across multiple regions. Recent surges in cases have heightened global health concerns and prompted urgent responses from governments and health organizations. Agencies such as the World Health Organization have emphasized surveillance, vaccination, and outbreak control strategies, leading to increased demand for effective vaccines. Growing awareness about zoonotic diseases and their potential to cause widespread public health emergencies is further accelerating vaccination efforts. This heightened focus on disease prevention and rapid response is significantly driving market growth.
Another key driver is the rising focus on pandemic preparedness and strategic vaccine stockpiling by governments worldwide. Following recent global health crises, countries are investing in maintaining emergency reserves of vaccines to respond quickly to potential outbreaks. This includes procurement agreements and funding support for vaccine manufacturers to ensure consistent supply. Additionally, advancements in vaccine technology and increased funding for research and development are enhancing the availability of safer and more effective vaccines. These proactive measures by governments and public health agencies are playing a crucial role in expanding the global monkeypox vaccine market.
Market Restraints:
The key restraints in the global monkeypox vaccine market is the limited availability of approved vaccines and constrained production capacity. Currently, only a few manufacturers produce monkeypox vaccines, leading to supply shortages during sudden outbreak surges. The complex manufacturing process, strict regulatory requirements, and reliance on specialized facilities further restrict rapid scale-up of production. This creates challenges for timely distribution, especially in low- and middle-income countries. Additionally, high procurement costs and unequal global access can hinder widespread immunization efforts. These supply-side limitations significantly impact market growth despite rising global demand for monkeypox vaccines.
The global monkeypox vaccine market has a notable socio-economic impact by strengthening public health systems and reducing the risk of widespread outbreaks. Effective vaccination helps control disease transmission, minimizing healthcare costs and preventing economic disruptions caused by quarantines and reduced workforce productivity. It also supports global health security by improving preparedness for emerging infectious diseases. The market drives investments in vaccine research, manufacturing, and distribution, creating employment opportunities in the healthcare and biotechnology sectors. However, unequal access and high costs may create disparities between regions. Thus, the market contributes to improved health outcomes, economic stability, and enhanced pandemic preparedness worldwide.
Segmental Analysis:
The non-replicating vaccines segment dominates the global monkeypox vaccine market due to its enhanced safety profile and lower risk of adverse effects. These vaccines do not replicate within the host, making them highly suitable for immunocompromised individuals and large-scale immunization programs. Their strong efficacy combined with improved tolerability has led to increased preference among healthcare providers and regulatory bodies. Growing adoption in outbreak control strategies and government vaccination campaigns is further supporting segment growth.
The smallpox-based vaccines segment holds a leading position as existing smallpox vaccines have shown effectiveness against monkeypox due to cross-protection. These vaccines are widely available and have established regulatory approvals, enabling rapid deployment during outbreaks. Governments rely on these vaccines for emergency stockpiling and immunization strategies. Their proven track record and availability make them a key contributor to market growth.
The subcutaneous route of administration dominates the market due to its ease of use and widespread acceptance in vaccination programs. It allows for efficient delivery of vaccines with minimal training requirements for healthcare professionals. This method is commonly used in mass immunization campaigns and offers reliable immune response outcomes. Increasing vaccination drives and public health initiatives are further boosting demand for this route.
The post-exposure prophylaxis segment leads the market as vaccination after exposure is a critical strategy to prevent disease progression and control outbreaks. Health authorities prioritize vaccinating close contacts of infected individuals to limit virus spread. This approach has been widely implemented in recent outbreak responses, increasing demand for vaccines in emergency situations. Growing awareness and rapid response mechanisms are further driving this segment.
Public health agencies represent the largest end user segment due to their central role in managing vaccination campaigns and outbreak control programs. Governments and international health organizations coordinate large-scale vaccine distribution through these agencies to ensure wide population coverage. Their involvement ensures efficient procurement, storage, and administration of vaccines. Increasing government funding and global health initiatives further strengthen this segment’s dominance.
North America holds a dominant position in the global monkeypox vaccine market due to advanced healthcare infrastructure, strong government support, and high awareness regarding infectious diseases. The region has actively implemented vaccination programs and secured large vaccine supplies to manage outbreaks. Presence of key pharmaceutical companies and robust research capabilities further support market growth. Additionally, favorable regulatory frameworks and high healthcare spending enhance adoption.
The global monkeypox vaccine market is highly concentrated, with a limited number of pharmaceutical and biotechnology companies actively involved in vaccine development, production, and supply. The market is largely dominated by Bavarian Nordic, which produces the only widely approved monkeypox vaccine (JYNNEOS/IMVANEX), creating a significant competitive advantage. Competition is gradually increasing as other pharmaceutical companies and biotech firms invest in next-generation vaccines, expand manufacturing capabilities, and collaborate with governments and global health organizations. Strategic partnerships, technology licensing, and public-private collaborations are key competitive strategies. Additionally, rising demand during outbreaks is encouraging new entrants and contract manufacturers to participate, making the market more dynamic despite current supply concentration.
Key Companies:
Q1. What are the main growth-driving factors for this market?
Market growth is primarily driven by recurring global outbreaks and the World Health Organization's (WHO) designation of Mpox as a public health emergency. This has spurred massive government funding, international procurement agreements, and substantial biodefense stockpiling initiatives to secure long-term health security and pandemic preparedness budgets worldwide.
Q2. What are the main restraining factors for this market?
The market is primarily restrained by the high cost of advanced, non-replicating vaccines, making them inaccessible to general populations in lower-income, endemic African regions. Strict regulatory compliance pathways, high clinical trial failure rates, and logistical challenges in maintaining cold-chain distribution across remote areas further limit rapid global market expansion.
Q3. Which segment is expected to witness high growth?
The Prophylactic Vaccines / Preventive Immunization segment is witnessing high growth, driven by urgent national vaccination campaigns targeting high-risk populations. Technically, the Non-Replicating Vaccines segment (such as MVA-BN) dominates market interest due to its superior safety profile and lower risk of adverse reactions compared to older replicating platforms.
Q4. Who are the top major players for this market?
The competitive landscape is led by prominent biotechnology and defense-pharma specialists, including Bhavarian Nordic (JYNNEOS / IMVANEX) and Emergent BioSolutions (ACAM2000). Other significant players driving advanced pipelines—including next-generation mRNA technologies—include Moderna Therapeutics, BioNTech SE, Chimerix, SIGA Technologies, and Tonix Pharmaceuticals.
Q5. Which country is the largest player?
The United States is the largest country player, anchoring North America’s dominant 40% plus share of the global market in 2026. This leadership is sustained by the world's largest strategic national biodefense stockpiling program, extensive CDC-backed public health frameworks, robust R&D funding, and highly advanced healthcare infrastructure.
Data Library Research are conducted by industry experts who offer insight on industry structure, market segmentations technology assessment and competitive landscape (CL), and penetration, as well as on emerging trends. Their analysis is based on primary interviews (~ 80%) and secondary research (~ 20%) as well as years of professional expertise in their respective industries. Adding to this, by analysing historical trends and current market positions, our analysts predict where the market will be headed for the next five years. Furthermore, the varying trends of segment & categories geographically presented are also studied and the estimated based on the primary & secondary research.
In this particular report from the supply side Data Library Research has conducted primary surveys (interviews) with the key level executives (VP, CEO’s, Marketing Director, Business Development Manager and SOFT) of the companies that active & prominent as well as the midsized organization
FIGURE 1: DLR RESEARH PROCESS
Extensive primary research was conducted to gain a deeper insight of the market and industry performance. The analysis is based on both primary and secondary research as well as years of professional expertise in the respective industries.
In addition to analysing current and historical trends, our analysts predict where the market is headed over the next five years.
It varies by segment for these categories geographically presented in the list of market tables. Speaking about this particular report we have conducted primary surveys (interviews) with the key level executives (VP, CEO’s, Marketing Director, Business Development Manager and many more) of the major players active in the market.
Secondary ResearchSecondary research was mainly used to collect and identify information useful for the extensive, technical, market-oriented, and Friend’s study of the Global Extra Neutral Alcohol. It was also used to obtain key information about major players, market classification and segmentation according to the industry trends, geographical markets, and developments related to the market and technology perspectives. For this study, analysts have gathered information from various credible sources, such as annual reports, sec filings, journals, white papers, SOFT presentations, and company web sites.
Market Size EstimationBoth, top-down and bottom-up approaches were used to estimate and validate the size of the Global market and to estimate the size of various other dependent submarkets in the overall Extra Neutral Alcohol. The key players in the market were identified through secondary research and their market contributions in the respective geographies were determined through primary and secondary research.
Forecast Model